News, reviews and podcasts from annual scientific meetings and symposiums around the world.
“In the NICHE-2 study, two cycles of neoadjuvant nivolumab plus low-dose ipilimumab led to unprecedented…
Study lead Jean-Pascal Machiels, Cliniques Universitaires Saint-Luc (UCLouvain) and Institut de Recherche Clinique et Expérimentale (Pole…
Newly released results from the Phase III ADAURA trial reveal that osimertinib yielded a 5.5-year…
“COSMIC-313 is the first metastatic renal cell carcinoma (RCC) phase 3 trial with a doublet…
8 in 10 Europeans believe tans are attractive with almost as many (73%) saying tans…
“Even with notable progress in the treatment of metastatic renal cell carcinoma (RCC), there are…
“In the first Phase 3 randomised clinical trial for a KRASG12C inhibitor, oral sotorasib demonstrated…
A novel treatment strategy with personalised cell therapy significantly improves progression-free survival compared to standard…
Newly released results from the Phase III ADAURA trial reveal that osimertinib yielded a 5.5-year…
Cancer doctors, care providers and payers need to get ready for a major shift in…